Sintofarm SA Bucuresti
BBVB:SINT10.20
RON
-4.10
(-28.67%)
ISIN
ROSINTACNOR6
Return %
Stock
S&P 500
1Y
137.21
14.20
3Y
191.43
81.12
5Y
87.16
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Bucharest Romania
- IPO Date
- Feb 20, 1997
- Website
- sintofarm.ro
- Similar Companies
- Business
- Sintofarm SA Bucuresti is a Romania-based pharmaceutical manufacturing and commercial real estate company. The company specializes in the development, production, and distribution of human pharmaceuticals, medical devices, and chemical products across multiple operational segments: prescription and over-the-counter pharmaceuticals, including gastrointestinal treatments such as Saprosan, analgesics, anti-inflammatories, cardiovascular formulations, and neurotropic medications; hospital-grade and institutional disinfectants and biocidal products, featuring Cloramina T tablets and Hexigel Forte formulations; medical devices and specialty health preparations, including nasal spray solutions, topical arnica and hyaluronic acid gels, rectal creams, and pediatric and adult microenemas; rapid diagnostic test kits; food supplements; and cosmetic formulations. In addition to chemical and pharmaceutical manufacturing, the company provides industrial property leasing, warehouse rental, and real estate development services. Sintofarm SA supplies public healthcare institutions, hospitals, commercial pharmacy chains, industrial clients, and consumer markets domestically across Romania, as well as international clients through export operations. In recent developments, the company has strategically advanced the commercial valorization and urban redevelopment of its primary real estate assets in Bucharest, progressing licensing and urban planning documentation for large-scale mixed-use residential and commercial development projects on its industrial landholdings. Operationally, Sintofarm SA has optimized its product portfolio to concentrate on high-demand biocides and medical devices while expanding long-term commercial leasing agreements across its facilities to diversify revenue streams. The company traces its operational roots to the establishment of Nitranil in 1946, was incorporated in its current joint-stock structure in 1991, and is headquartered in Bucharest, Romania, trading on the Bucharest Stock Exchange under the ticker symbol SINT.